Biology & Life Sciences

Triple drug (IDA) mass drug administration for elimination of lymphatic filariasis

Published June 16, 2022

This collection reports results of clinical trials and community studies of the safety, efficacy, and acceptability of the triple drug regimen IDA (ivermectin plus DEC and Albendazole) as a mass drug administration (MDA) regimen for lymphatic filariasis (LF) elimination programmes. As a group, these papers provide a comprehensive record of how these linked studies helped IDA to make the transition from research discovery to policy change and implementation. Data from these studies supported WHO’s decision to endorse IDA as a tool to accelerate LF elimination in many settings, and tens of millions of people now receive IDA each year.

Jump to section

PLOS Medicine
PLOS Neglected Tropical Diseases

PLOS Medicine

Image credit
10.1371/journal.pmed.1003849 CC BY 4.0

PLOS Medicine Community control strategies for scabies: A cluster randomised noninferiority trial
November 10, 2021 Myra Hardy, Josaia Samuela, Mike Kama, Meciusela Tuicakau, Lucia Romani, Margot J. Whitfeld, Christopher L. King, Gary J. Weil, Tibor Schuster, Anneke C. Grobler, Daniel Engelman, Leanne J. Robinson, John M. Kaldor, Andrew C. Steer

Background: Scabies is a neglected tropical disease hyperendemic to many low- and middle-income countries. Scabies can be successfully…
Image credit
10.1371/journal.pmed.1002839 CC BY 4.0

PLOS Medicine The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study
June 24, 2019 Gary J. Weil, Joshua Bogus, Michael Christian, Christine Dubray, Yenny Djuardi, Peter U. Fischer, Charles W. Goss, Myra Hardy, Purushothaman Jambulingam, Christopher L. King, Vijesh Sridhar Kuttiat, Kaliannagounder Krishnamoorthy, Moses Laman, Jean Frantz Lemoine, Katiuscia K. O’Brian, Leanne J. Robinson, Josaia Samuela, Kenneth B. Schechtman, Anita Sircar, Adinarayanan Srividya, Andrew C. Steer, Taniawati Supali, Swaminathan Subramanian, the DOLF IDA Safety Study Group

Background: The Global Programme to Eliminate Lymphatic Filariasis (GPELF) provides antifilarial medications to hundreds of millions of…

PLOS Neglected Tropical Diseases

Image credit
10.1371/journal.pntd.0010096 CC BY 4.0

PLOS Neglected Tropical Diseases Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial
February 9, 2022 Livingstone Tavul, Moses Laman, Cade Howard, Bethuel Kotty, Anna Samuel, Catherine Bjerum, Kobie O’Brian, Steven Kumai, Matthew Amuga, Lina Lorry, Zebedee Kerry, Melvin Kualawi, Stephan Karl, Leo Makita, Lucy N. John, Sibauk Bieb, James Wangi, Gary J. Weil, Charles W. Goss, Daniel J. Tisch, William Pomat, Christopher L. King, Leanne J. Robinson

Background: Papua New Guinea (PNG) has a high burden of lymphatic filariasis (LF) caused by Wuchereria bancrofti, with an estimated 4.2…
Image credit
10.1371/journal.pntd.0009294 CC BY 4.0

PLOS Neglected Tropical Diseases An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia
March 29, 2021 Taniawati Supali, Yenny Djuardi, Michael Christian, Elisa Iskandar, Rahmat Alfian, Roospita Maylasari, Yossi Destani, Adriani Lomiga, Dominikus Minggu, Daphne Lew, Joshua Bogus, Gary J. Weil, Peter U. Fischer

Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug…
Image credit
10.1371/journal.pntd.0009069 CC BY 4.0

PLOS Neglected Tropical Diseases An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India
February 16, 2021 Purushothaman Jambulingam, Vijesh Sreedhar Kuttiatt, Kaliannagounder Krishnamoorthy, Swaminathan Subramanian, Adinarayanan Srividya, Hari Kishan K. Raju, Manju Rahi, Roopali K. Somani, Mallanna K. Suryaprakash, Gangeshwar P. Dwivedi, Gary J. Weil

Background: Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis…
Image credit
10.1371/journal.pntd.0009002 CC BY 4.0

PLOS Neglected Tropical Diseases A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis
March 3, 2021 Alison Krentel, Nandha Basker, Madsen Beau de Rochars, Joshua Bogus, Daniel Dilliott, Abdel N. Direny, Christine Dubray, Peter U. Fischer, Adriani Lomi Ga, Charles W. Goss, Myra Hardy, Cade Howard, Purushothaman Jambulingam, Christopher L. King, Moses Laman, Jean Frantz Lemoine, Shruti Mallya, Leanne J. Robinson, Josaia Samuela, Ken B. Schechtman, Andrew C. Steer, Taniawati Supali, Livingstone Tavul, Gary J. Weil

Background: Many countries will not reach elimination targets for lymphatic filariasis in 2020 using the two-drug treatment regimen…
Image credit
10.1371/journal.pntd.0008298 CC BY 4.0

PLOS Neglected Tropical Diseases Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study
June 8, 2020 Christine L. Dubray, Anita D. Sircar, Valery Madsen Beau de Rochars, Joshua Bogus, Abdel N. Direny, Jean Romuald Ernest, Carl R. Fayette, Charles W. Goss, Marisa Hast, Kobie O’Brian, Guy Emmanuel Pavilus, Daniel Frantz Sabin, Ryan E. Wiegand, Gary J. Weil, Jean Frantz Lemoine

In Haiti, 22 communes still require mass drug administration (MDA) to eliminate lymphatic filariasis (LF) as a public health problem.…
Image credit
10.1371/journal.pntd.0008106 CC BY 4.0

PLOS Neglected Tropical Diseases The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
March 16, 2020 Myra Hardy, Josaia Samuela, Mike Kama, Meciusela Tuicakau, Lucia Romani, Margot J. Whitfeld, Christopher L. King, Gary J. Weil, Anneke C. Grobler, Leanne J. Robinson, John M. Kaldor, Andrew C. Steer

Lymphatic filariasis has remained endemic in Fiji despite repeated mass drug administration using the well-established and safe…
Image credit
10.1371/journal.pntd.0007541 CC BY 4.0

PLOS Neglected Tropical Diseases Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach
July 17, 2019 Charles W. Goss, Katiuscia O’Brian, Christine Dubray, Peter U. Fischer, Myra Hardy, Purushothaman Jambulingam, Christopher L. King, Moses Laman, Jean Frantz Lemoine, Leanne J. Robinson, Josaia Samuela, Swaminathan Subramanian, Taniawati Supali, Gary J. Weil, Kenneth B. Schechtman

Background: The World Health Organization (WHO) currently recommends height or age-based dosing as alternatives to weight-based dosing for…
Image credit
10.1371/journal.pntd.0007325 CC BY 4.0

PLOS Neglected Tropical Diseases Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d’Ivoire
May 20, 2019 Constant Edi, Catherine M. Bjerum, Allassane F. Ouattara, Yashpal S. Chhonker, Louis K. Penali, Aboulaye Méité, Benjamin G. Koudou, Gary J. Weil, Christopher L. King, Daryl J. Murry

Background: A single co-administered dose of ivermectin (IVM) plus diethylcarbamazine (DEC) plus albendazole (ALB), or triple-drug therapy,…
Image credit
10.1371/journal.pntd.0005163 CC BY 4.0

PLOS Neglected Tropical Diseases Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa
January 5, 2017 Peter U. Fischer, Christopher L. King, Julie A. Jacobson, Gary J. Weil

…

READY TO SUBMIT?

Make your research discoverable with PLOS.

Submit now!

FOLLOW PLOS NTDs ON TWITTER

To keep up to date on the latest research.